Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Immunotherapy, Active”

229 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 229 results

Early research (Phase 1)Looking for participantsNCT07538479
What this trial is testing

Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)

Who this might be right for
Solid TumorsSolid MalignanciesCold Exposure+1 more
West China Hospital 24
Early research (Phase 1)Ended earlyNCT03162562
What this trial is testing

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

Who this might be right for
Cancer of OvaryNeoplasms, OvarianOvarian Cancer Stage IV+3 more
CanariaBio Inc. 10
Testing effectiveness (Phase 2)Looking for participantsNCT07589530
What this trial is testing

Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Solid TumorsTROP2-Expressing Solid Tumors
Beijing Biotech 60
Early research (Phase 1)Ended earlyNCT05904496
What this trial is testing

BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors
BeiGene 44
Testing effectiveness (Phase 2)Looking for participantsNCT04422912
What this trial is testing

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Who this might be right for
Pemphigus Vulgaris
Cabaletta Bio 40
Testing effectiveness (Phase 2)Ended earlyNCT02054104
What this trial is testing

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

Who this might be right for
Thoracic SarcomasThorasic CancersCancers of Non-thoracic Origin With Metastases to the Lungs or Pleura+2 more
National Cancer Institute (NCI) 21
Testing effectiveness (Phase 2)Study completedNCT00002475
What this trial is testing

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Who this might be right for
Breast CancerColorectal CancerKidney Cancer+3 more
St. Vincent Medical Center - Los Angeles 40
Early research (Phase 1)Ended earlyNCT05233436
What this trial is testing

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorsGastric CancerGastroesophageal Junction Cancer+3 more
Pfizer 21
Early research (Phase 1)Study completedNCT00108264
What this trial is testing

Tumor RNA Transfected Dendritic Cell Vaccines

Who this might be right for
Prostate Cancer
US Department of Veterans Affairs
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07110662
What this trial is testing

New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.

Who this might be right for
Toxic Epidermal NecrolysisImmunotherapyCutaneous Adverse Drug Reactions (CADR)
Hospices Civils de Lyon 9
Large-scale testing (Phase 3)Looking for participantsNCT06339060
What this trial is testing

An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).

Who this might be right for
Esophageal Cancer
Ruijin Hospital 356
Early research (Phase 1)Ended earlyNCT04628780
What this trial is testing

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

Who this might be right for
Non-small-cell Lung CancerSquamous Cell Carcinoma of the Head and NeckRenal Cell Carcinoma+3 more
Pfizer 37
Testing effectiveness (Phase 2)Study completedNCT00001934
What this trial is testing

Zenapax to Treat Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
National Institute of Neurological Disorders and Stroke (NINDS) 22
Testing effectiveness (Phase 2)WithdrawnNCT01437020
What this trial is testing

SCH708980 With and Without AmBisome for Visceral Leishmaniasis

Who this might be right for
LeishmaniasisEffects of Immunotherapy
National Institute of Allergy and Infectious Diseases (NIAID)
Testing effectiveness (Phase 2)Study completedNCT00948480
What this trial is testing

Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells

Who this might be right for
Metastatic Melanoma
Hoag Memorial Hospital Presbyterian 56
Testing effectiveness (Phase 2)Study completedNCT03008499
What this trial is testing

High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Fuda Cancer Hospital, Guangzhou 20
Testing effectiveness (Phase 2)Ended earlyNCT04445064
What this trial is testing

Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.

Who this might be right for
Oropharynx Squamous Cell CarcinomaLarynx Squamous Cell CarcinomaHypopharynx Squamous Cell Carcinoma+1 more
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 17
Testing effectiveness (Phase 2)Ended earlyNCT02010203
What this trial is testing

HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

Who this might be right for
Bladder Cancer
Heat Biologics 104
Testing effectiveness (Phase 2)Looking for participantsNCT05824975
What this trial is testing

Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more
GI Innovation, Inc. 358
Testing effectiveness (Phase 2)Study completedNCT02614833
What this trial is testing

IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma

Who this might be right for
Adenocarcinoma Breast Stage IV
Immutep S.A.S. 242
Load More Results